c-Myc & EpCAM Antibodies: Core Tools for Tumor Immunology and Precision Oncology Research

Concept

Tumor initiation, progression and immune evasion are governed by two critical molecular pillars: master transcriptional regulators that orchestrate oncogenic programs (proliferation, metabolism, microenvironment remodeling) and tumor-specific cell surface antigens that define cancer identity and enable precision detection/therapy. c-Myc, a proto-oncogenic transcription factor, is a central node in tumor biology—its aberrant overexpression drives cell proliferation, metabolic reprogramming and the immunosuppressive tumor microenvironment (TME), making it a key target for understanding tumor-immune interactions. Epithelial Cell Adhesion Molecule (EpCAM, CD326), a unique transmembrane glycoprotein, is the gold-standard marker for epithelial-derived tumors, with tumor-specific overexpression enabling circulating tumor cell (CTC) isolation, pathological classification and targeted therapy development. Unraveling the complex mechanisms of tumor biology and advancing precision oncology demands highly specific, multi-platform validated antibodies: c-Myc antibodies for dissecting oncogenic transcriptional regulation and TME remodeling, and EpCAM antibodies for epithelial tumor detection, liquid biopsy and targeted therapy research. As a global leader in life science reagents, ANT BIO PTE. LTD. delivers cutting-edge antibodies for both targets via its Starter sub-brand (our flagship line for high-performance, rigorously validated antibodies): the S-RMab® c-Myc Recombinant Rabbit Monoclonal Antibody (S0B2165) and the S-RMab® EpCAM Recombinant Rabbit Monoclonal Antibody (S0B2028). Engineered on the proprietary S-RMab® recombinant rabbit monoclonal platform, these antibodies offer ultra-specificity, exceptional cross-species/applicability performance and batch-to-batch consistency—serving as indispensable gold-standard tools for tumor immunology, precision diagnosis, targeted therapy development and basic cancer biology research worldwide.

Research Frontiers

c-Myc and EpCAM research are at the forefront of modern tumor biology, immunotherapy and precision oncology, addressing unmet needs in understanding oncogenic mechanisms, early cancer detection and targeted therapy innovation. ANT BIO PTE. LTD.’s specialized c-Myc and EpCAM antibodies enable transformative discoveries in key high-impact research frontiers that are redefining our approach to cancer diagnosis and treatment:

c-Myc in Tumor Immunology and Oncogenic Regulation

1. c-Myc-mediated TME remodeling: Dissecting how c-Myc overexpression modulates immune cell infiltration (effector T cells, tumor-associated macrophages), upregulates immune checkpoints (PD-L1) and drives metabolic competition in the TME—uncovering novel mechanisms of tumor immune evasion.
2. Intratumoral heterogeneity targeting: Developing smart genetic circuit and exosome delivery systems that sense c-Myc expression levels to overcome treatment resistance caused by heterogeneous c-Myc expression in solid tumors and hematologic malignancies.
3. c-Myc-targeted combination immunotherapy: Exploring synergistic effects of c-Myc inhibition with immune checkpoint inhibitors (ICIs), cytokine therapies and CAR-T cell therapy—designing rational combination regimens to reverse immunosuppression and enhance anti-tumor immunity.
4. c-Myc as a predictive biomarker: Validating c-Myc expression levels as a predictive biomarker for ICI response, chemotherapy efficacy and patient prognosis—enabling personalized treatment decision-making for cancer patients.
5. Post-translational modification of c-Myc: Studying how phosphorylation (Ser62) and other PTMs regulate c-Myc stability, transcriptional activity and oncogenic function—identifying novel therapeutic targets for c-Myc modulation.

EpCAM in Epithelial Tumor Precision Diagnosis and Therapy

1. Next-generation liquid biopsy: Engineering EpCAM antibody-based microfluidic and magnetic capture systems for high-sensitivity, single-cell analysis of EpCAM-positive CTCs—enabling early detection, minimal residual disease (MRD) monitoring and genomic profiling of metastatic epithelial cancers.
2. EpCAM-targeted therapeutic innovation: Developing EpCAM antibody-drug conjugates (ADCs), bispecific antibodies and CAR-T cell therapies for refractory epithelial cancers (colorectal, breast, pancreatic, lung)—optimizing tumor selectivity to reduce off-target toxicity in normal epithelial tissues.
3. EpCAM in cancer stem cell (CSC) research: Identifying and characterizing EpCAM-positive CSC subpopulations in epithelial tumors—dissecting EpCAM-mediated signaling pathways that drive CSC self-renewal, metastasis and therapy resistance.
4. Spatial pathology and EpCAM expression: Combining EpCAM antibody-based staining with spatial transcriptomics and multiplex immunofluorescence to map EpCAM expression in the TME—correlating expression with immune cell infiltration and angiogenesis for precision therapy design.
5. Soluble EpCAM (sEpCAM) as a serum biomarker: Validating sEpCAM detection via EpCAM antibodies as a non-invasive biomarker for epithelial cancer diagnosis, progression monitoring and treatment response assessment.

Research Significance

c-Myc and EpCAM are defining molecular targets in cancer research, with their study driving paradigm shifts in our understanding of oncogenic mechanisms, tumor immunology and precision oncology. ANT BIO PTE. LTD.’s c-Myc and EpCAM antibodies amplify the scientific and translational significance of this research, with far-reaching implications for cancer diagnosis, therapy and patient care:

c-Myc: The Master Regulator of Oncogenic Programs and Tumor Immunity

1. A unifying oncogenic node: c-Myc is aberrantly overexpressed in over 70% of human malignancies, regulating a network of >15% of all human genes to drive cell proliferation, metabolic reprogramming (Warburg effect, glutamine addiction) and cell survival—making it a central target for understanding the core oncogenic program of cancer.
2. Linking cell-intrinsic oncogenicity to the TME: c-Myc is the first identified transcription factor that directly connects tumor cell-intrinsic characteristics to TME immunosuppression—its overexpression reshapes the TME by inhibiting anti-tumor immune cells and promoting pro-tumor immune phenotypes, providing a unique target for combining oncogene inhibition and immunotherapy.
3. Key to overcoming immunotherapy resistance: Heterogeneous c-Myc expression is a major cause of immunotherapy resistance; targeting c-Myc or its downstream pathways reverses TME immunosuppression and restores anti-tumor immunity, offering a new strategy for treating ICI-refractory cancers.
4. A predictive biomarker for precision oncology: c-Myc expression levels correlate with tumor grade, metastasis and treatment response—accurate detection via specific antibodies enables risk stratification and personalized treatment selection for cancer patients.

EpCAM: The Gold-Standard Marker for Epithelial Cancer Precision Medicine

1. Universal epithelial tumor identification: EpCAM is overexpressed in nearly all epithelial-derived cancers (adenocarcinoma, squamous cell carcinoma) but minimally expressed in non-epithelial tumors (sarcomas, lymphomas) and normal stroma—making it the most specific and widely used marker for pathological classification of epithelial cancers, a critical step in clinical diagnosis.
2. Enabling non-invasive liquid biopsy: EpCAM is the primary target for CTC isolation from peripheral blood, a transformative liquid biopsy technology that has revolutionized cancer staging, MRD monitoring and treatment response assessment—eliminating the need for invasive tissue biopsies in metastatic patients.
3. Ideal for targeted therapy development: EpCAM’s cell surface localization and tumor-specific expression make it a prime target for antibody-based therapeutics (ADCs, bispecific antibodies, CAR-T)—EpCAM-targeted therapies show promising efficacy in preclinical and clinical studies for refractory epithelial cancers.
4. Core marker for cancer stem cell research: EpCAM is a defining marker for EpCAM-positive CSCs in epithelial tumors, which are responsible for tumor initiation, metastasis and therapy resistance—dissecting EpCAM-mediated CSC function is critical for developing curative cancer therapies.

Together, these two molecular targets and the high-specificity antibodies that detect them form the backbone of modern cancer research, enabling the transition from one-size-fits-all cancer treatment to personalized precision oncology and immunotherapy.

Related Mechanisms, Research Methods & Product Applications

1. c-Myc: Molecular Function and Mechanisms in Tumor Biology & Immunology

c-Myc is a 60-65 kDa proto-oncogenic transcription factor encoded by the MYC gene, a key regulator of cell proliferation, differentiation, metabolic reprogramming and apoptosis. As a master transcriptional regulator, c-Myc forms heterodimers with Max to bind E-box motifs in the promoter regions of target genes, orchestrating the expression of a vast network of genes involved in core cellular processes. In cancer cells, aberrant c-Myc overexpression/amplification drives tumor development and immune evasion through four key mechanisms:

• Cell proliferation and survival: Upregulates genes involved in cell cycle progression (cyclins, CDKs) and anti-apoptosis (Bcl-2), promoting uncontrolled tumor cell proliferation and resistance to cell death.
• Metabolic reprogramming: Induces the Warburg effect (aerobic glycolysis) and glutamine addiction, meeting the high energy and biosynthetic demands of rapidly proliferating tumor cells while depleting nutrients (glucose, glutamine) in the TME to inhibit immune cell function.
• TME immunosuppression: Upregulates PD-L1 and other immune checkpoint molecules on tumor cells, polarizes tumor-associated macrophages (TAMs) to an immunosuppressive M2 phenotype, and inhibits the infiltration and activation of effector T cells and natural killer (NK) cells.
• Intratumoral heterogeneity: Heterogeneous c-Myc expression across tumor cell subpopulations creates distinct TME regions with varying levels of immunosuppression, leading to treatment resistance and tumor recurrence.

Core Applications of c-Myc Antibodies in Tumor Research

c-Myc-specific antibodies are indispensable tools for basic and translational cancer research, with diverse applications across key experimental platforms and research areas:

1. Expression and localization analysis: Immunohistochemistry (IHC), immunofluorescence (IF) and Western blot (WB) to detect c-Myc expression levels and subcellular localization (nuclear, the primary site of c-Myc function) in tumor tissues and cell lines—providing evidence for tumor grading, prognosis and molecular classification.
2. Protein interaction and signaling studies: Co-immunoprecipitation (Co-IP) to capture c-Myc-interacting protein complexes (Max, transcriptional co-factors)—unraveling c-Myc’s functional positioning in oncogenic signaling networks.
3. Transcriptional regulation analysis: Chromatin immunoprecipitation (ChIP) to identify c-Myc’s direct target genes and map its binding sites on the genome—defining the c-Myc-mediated transcriptional network in cancer.
4. Therapy response monitoring: WB and IHC to monitor changes in c-Myc expression levels during targeted therapy/immunotherapy—evaluating treatment efficacy and predicting the development of drug resistance.
5. Post-translational modification research: Phospho-specific c-Myc (Ser62) antibodies to study c-Myc phosphorylation—elucidating how PTMs regulate c-Myc stability and transcriptional activity in cancer.

2. EpCAM: Molecular Structure, Expression and Mechanisms in Epithelial Tumors

Epithelial Cell Adhesion Molecule (EpCAM, CD326) is a 33-40 kDa (glycosylation-dependent) type I transmembrane glycoprotein encoded by the TACSTD1 (GA733-2) gene on human chromosome 4, with a unique 314-amino acid structure that does not belong to classical cell adhesion molecule families (integrins, selectins, cadherins). Its modular structure consists of three functional domains:

• A 242-amino acid extracellular domain (contains an EGF-like domain and a thyroglobulin-like repeat sequence) that mediates homotypic cell adhesion and has three potential N-glycosylation sites.
• A 23-amino acid single transmembrane domain that anchors the protein to the cell membrane.
• A 26-amino acid short intracellular domain that mediates downstream signaling pathways regulating cell proliferation and migration.

EpCAM forms tetrameric multimers on the cell surface and exhibits tumor-specific expression: low expression on the basolateral surface of normal epithelial cells, and marked upregulation in nearly all epithelial-derived cancers—with expression levels correlating with tumor grade and metastasis.

Core Applications of EpCAM Antibodies in Tumor Diagnosis & Therapy

EpCAM-specific antibodies are the gold-standard tools for epithelial cancer research and clinical diagnostics, with applications spanning pathological diagnosis, liquid biopsy, basic tumor biology and targeted therapy development:

1. Histopathological classification: IHC staining for EpCAM in FFPE tumor tissue sections to distinguish epithelial-derived cancers from non-epithelial tumors—often used in combination with cytokeratin (CK) antibodies for confirmatory diagnosis in surgical pathology.
2. Circulating tumor cell (CTC) detection: EpCAM antibody-based capture systems to isolate and count EpCAM-positive CTCs from peripheral blood—enabling non-invasive early cancer detection, MRD monitoring and treatment response assessment for metastatic epithelial cancers.
3. Cancer stem cell (CSC) research: Flow cytometry (FACS) using fluorescently conjugated EpCAM antibodies to sort EpCAM-positive CSC subpopulations from tumor cell suspensions—facilitating functional characterization of CSCs and the development of CSC-targeted therapies.
4. Targeted therapy development: EpCAM antibodies as the foundation for developing ADCs, bispecific antibodies and CAR-T cell therapies—validating EpCAM expression in tumor models and clinical samples for patient stratification and efficacy assessment.
5. Soluble EpCAM (sEpCAM) detection: ELISA using EpCAM antibodies to detect sEpCAM in patient serum—a potential non-invasive biomarker for epithelial cancer diagnosis and progression monitoring.

ANT BIO PTE. LTD.’s Starter Antibodies: Core Products for Tumor Research

ANT BIO PTE. LTD.’s Starter sub-brand delivers two industry-leading antibodies for c-Myc and EpCAM research—both engineered on the proprietary S-RMab® recombinant rabbit monoclonal platform and rigorously validated for ultra-specificity, exceptional multi-platform performance and batch-to-batch consistency. These antibodies are optimized for the unique experimental and clinical needs of tumor biology, immunology and precision oncology research, and serve as gold-standard tools for basic and translational cancer research worldwide.

1. S-RMab® c-Myc Recombinant Rabbit Monoclonal Antibody (S0B2165)

This high-performance antibody is a core tool for proto-oncogene and tumor biology research, with ultra-specificity for c-Myc (minimal cross-reactivity to N-Myc/L-Myc) and broad cross-species applicability (human, mouse, rat)—enabling cross-species comparative studies and preclinical research.

Core Product Advantages

Key Research Application Values

• Tumor diagnosis and prognostic assessment: Detects c-Myc overexpression/amplification in various malignancies (lymphoma, breast, lung, colorectal cancer) for pathological grading, molecular classification and prognosis prediction.
• Oncogenic signaling and transcriptional regulation: ChIP and Co-IP to dissect the c-Myc-mediated transcriptional network and its interaction with oncogenic signaling pathways (PI3K/Akt, MAPK).
• Metabolic reprogramming research: Studies c-Myc’s role in driving the Warburg effect and glutamine addiction—uncovering the link between c-Myc and tumor cell metabolism.
• Cell proliferation and stem cell research: Analyzes c-Myc’s regulation of cell cycle progression, stem cell self-renewal and differentiation in normal and cancerous cells.
• Targeted drug development: Screens and evaluates the efficacy of c-Myc-targeted drugs (small molecule inhibitors, PROTACs) and monitors c-Myc expression changes during therapy—validating drug mechanism of action.

2. S-RMab® EpCAM Recombinant Rabbit Monoclonal Antibody (S0B2028)

This ultra-specific antibody is the gold-standard tool for epithelial tumor research and clinical pathology, with exceptional specificity for the EpCAM extracellular domain and clear membrane staining in FFPE tissue sections—ideal for pathological diagnosis, CTC detection and EpCAM-targeted therapy research.

Core Product Advantages

Key Research & Clinical Application Values

• Epithelial tumor pathological diagnosis: Distinguishes epithelial-derived cancers from non-epithelial tumors (sarcomas, lymphomas) in FFPE sections—used in combination with CK series antibodies for confirmatory diagnosis.
• Circulating tumor cell (CTC) detection: Serves as a capture/detection antibody for enriching EpCAM-positive CTCs from peripheral blood—critical for liquid biopsy, prognostic assessment and treatment response monitoring.
• Cancer stem cell (CSC) research: FACS sorting of EpCAM-positive CSC subpopulations from tumor cell suspensions—facilitating functional characterization of CSCs and the development of CSC-targeted therapies.
• EpCAM-targeted therapy development: Validates EpCAM expression in tumor models and clinical samples for ADC, bispecific antibody and CAR-T cell therapy development—including patient stratification and efficacy assessment.
• Developmental biology & tissue engineering: Labels and tracks epithelial cells in organoid culture, regenerative medicine and developmental biology research—studying epithelial cell differentiation and tissue formation.

Brand Mission of ANT BIO PTE. LTD.

At ANT BIO PTE. LTD., our core mission is to empower breakthroughs in tumor biology, immunology and precision oncology by delivering high-quality, highly specific and rigorously validated life science reagents and comprehensive solutions. As a leading global provider of research tools, we have built three specialized, complementary sub-brands that cover the full spectrum of life science research needs, creating a seamless one-stop procurement experience for academic researchers, pathologists, biotech companies, pharmaceutical institutions and translational research labs worldwide:

• Starter: Our flagship sub-brand for high-performance antibodies and affinity tools, offering tumor research antibodies (c-Myc S0B2165, EpCAM S0B2028), glycosylation/PSMA/PSEN1 antibodies and isoform-specific recombinant rabbit monoclonals. Starter is dedicated to engineering ultra-specific, application-optimized antibodies for the most challenging frontier research areas—including oncogenic regulation, tumor immune evasion, epithelial cancer detection and precision oncology—with a focus on meeting the stringent technical requirements of modern molecular biology and clinical pathology.
• Absin: Our core sub-brand for general life science reagents and kits, providing OneStep ELISA Kits, IHC/ICC/IF detection kits, sample preparation reagents, cell culture media and basic immunology/oncology research tools. Absin engineers user-friendly, pre-optimized assay kits that streamline experimental workflows and deliver reliable, accurate results for routine and high-throughput research.
• UA: Our specialized sub-brand for high-purity, high-activity recombinant proteins and expression vectors, including recombinant cytokines, antibody heavy/light chain expression constructs, immunomodulatory proteins and gene editing vectors. UA enables seamless experimental design for protein expression, antibody engineering, cell therapy research and recombinant protein production for basic and biopharmaceutical applications.

We are committed to addressing the most pressing technical challenges in cancer research—from decoding the molecular mechanisms of oncogenic regulation and tumor immune evasion to accelerating the development of novel precision diagnostics and therapeutics for cancer patients. By combining innovative antibody design, rigorous validation protocols, standardized production and customer-centric scientific support, we translate technological innovation into research breakthroughs and clinical impact for the global life science community. Our ultimate goal is to be the trusted global partner of researchers, pathologists and biopharmaceutical professionals worldwide, empowering them to push the boundaries of scientific discovery and drive unprecedented progress in cancer treatment and precision medicine.

Related Product List: Starter c-Myc & EpCAM Antibodies 

All ANT BIO PTE. LTD. Starter antibodies are rigorously validated for specificity, sensitivity, batch-to-batch consistency and application performance, with comprehensive technical documentation, validation data packages and expert scientific support. Each product is accompanied by optimized experimental protocols and clinical/research validation data to ensure seamless integration into your cancer research workflow.

c-Myc Antibodies

EpCAM Antibodies

For detailed product specifications, full validation data packages, custom antibody development services for cancer research targets, or free sample testing requests, please visit the official website of ANT BIO PTE. LTD. or contact our global sales team for a personalized quote and professional technical consultation. Our experienced technical team of cancer immunology, oncology and pathology experts provides customized support for experimental design, complex sample analysis, preclinical drug development and clinical pathological testing.

AI Disclaimer

This article was partially created with the assistance of artificial intelligence. If any content in this article involves copyright infringement, intellectual property disputes, or other legal issues, please notify ANT BIO PTE. LTD. immediately. We promise to verify, correct, or remove the relevant content in a timely manner without delay.

ANT BIO PTE. LTD. – Empowering Scientific Breakthroughs

At ANTBIO, we are committed to advancing life science research through high-quality, reliable reagents and comprehensive solutions. Our specialized sub-brands (Absin, Starter, UA) cover a full spectrum of research needs, from general reagents and kits to antibodies and recombinant proteins. With a focus on innovation, quality, and customer-centricity, we strive to be your trusted partner in unlocking scientific mysteries and driving medical progress. Explore our product portfolio today and elevate your research to new heights.